 |
29 Diseases |  |
85 Trials |
|
85 Trials |  |
3645 News |  |
| «12...34353637383940414243444546» |
- || Blincyto (blinatumomab) / Astellas, Amgen
New P2 trial, Minimal residual disease: DLI-TARGET: Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab (clinicaltrials.gov) - Jun 12, 2019
P2, N=12, Recruiting, Sponsor: Ludwig-Maximilians - University of Munich
- | Rituxan (rituximab) / Roche, Biogen
Journal: Development of Bispecific Antibody Derivatives for Cancer Immunotherapy. (Pubmed Central) - Jun 7, 2019
Development of antibody-based immunotherapeutics has progressed from direct tumor-targeting, with antibodies such as rituximab, to blocking of immune checkpoints to reactivate antitumor immunity...A number of bispecific antibody formats have been reported, with the first FDA-approved bispecific antibody being blinatumomab, a so-called bispecific T cell engager (BiTE), which redirects and potently activates T cell immune responses...Only upon dual binding to and CD47 RTX-CD47 blocks CD47 "Don't eat me" signaling. Here, we provide a detailed protocol for the construction and functional evaluation of such a bispecific antibody derivative.
- |||| Blincyto (blinatumomab) / Astellas, Amgen
Clinical, CAR T-Cell Therapy: Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies | In Press in Clinical Hematology International, the Official journal of @TheIACH https://t.co/BgggEHcT9f (Twitter) - Jun 7, 2019
- | Blincyto (blinatumomab) / Astellas, Amgen
Clinical, FDA event, Journal: Eliminating MRD - FDA approval of blinatumomab for B-ALL in complete remission. (Pubmed Central) - May 24, 2019
Here, we provide a detailed protocol for the construction and functional evaluation of such a bispecific antibody derivative. No abstract available
- | Kymriah (tisagenlecleucel-T) / Novartis, Blincyto (blinatumomab) / Astellas, Amgen
Blincyto has mopped the floor with Kymriah (Twitter) - May 17, 2019
- | Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial completion date: NCI-2017-00596: Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 16, 2019
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
No abstract available Trial completion date: Nov 2021 --> Nov 2020
- | Blincyto (blinatumomab) / Astellas, Amgen
Clinical, Journal, Residual disease: Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia. (Pubmed Central) - May 15, 2019
P2
Following treatment with blinatumomab in a population of patients with MRD-positive B-cell precursor ALL, the majority achieved a complete MRD response, which was associated with significantly longer RFS and OS compared with MRD nonresponders. The study is registered to https://clinicaltrials.gov as NCT01207388.
- | Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Clinical, Journal: Adult acute lymphoblastic leukemia: update on pathophysiology and management (Pubmed Central) - May 15, 2019
Furthermore, comprehensive genetic analyses using next generation sequencing technology have recently discovered new recurrent fusion genes of ALL, such as DUX4 fusion genes, ZNF384 fusion genes, and MEF2D fusion genes. In this review, I will introduce these frontline studies and discuss about the treatment of patients with adult ALL.
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial initiation date: Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL (clinicaltrials.gov) - May 13, 2019
P1, N=10, Not yet recruiting, Sponsor: Cedars-Sinai Medical Center
In this review, I will introduce these frontline studies and discuss about the treatment of patients with adult ALL. Initiation date: Dec 2018 --> Jul 2019
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date: Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 13, 2019
P2, N=30, Recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Dec 2018 --> Jul 2019 Trial completion date: Aug 2021 --> Aug 2020
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Minimal residual disease: Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease (clinicaltrials.gov) - May 13, 2019
P2, N=40, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Aug 2021 --> Aug 2020 Trial completion date: Sep 2020 --> Sep 2021
- | Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial completion date: NCI-2017-00596: Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 13, 2019
P2, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Sep 2020 --> Sep 2021 Trial completion date: Nov 2020 --> Nov 2021
- | Blincyto (blinatumomab) / Astellas, Amgen
Journal: Blinatumomab for MRDB-ALL: the evidence strengthens. (Pubmed Central) - May 11, 2019
Trial completion date: Nov 2020 --> Nov 2021 No abstract available
- | Blincyto (blinatumomab) / Astellas, Amgen, Opdivo (nivolumab) / BMS, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date: Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation (clinicaltrials.gov) - May 9, 2019
P2, N=21, Recruiting, Sponsor: M.D. Anderson Cancer Center
No abstract available Trial completion date: Jun 2021 --> Jun 2020
- | Blincyto (blinatumomab) / Astellas, Amgen, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Combination therapy, PD(L)-1 Biomarker: Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 3, 2019
P1/2, N=36, Recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Jun 2021 --> Jun 2020 Not yet recruiting --> Recruiting
- || Blincyto (blinatumomab) / Astellas, Amgen, Rituxan (rituximab) / Roche
New P2 trial: BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation (clinicaltrials.gov) - Apr 29, 2019
P2, N=35, Not yet recruiting, Sponsor: French Innovative Leukemia Organisation
- | Blincyto (blinatumomab) / Astellas, Amgen
Clinical, Journal: Outcome of Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia after Blinatumomab Failure: No Change in the Level of CD19 Expression. (Pubmed Central) - Apr 28, 2019
In summary, the outcome of patients with R/R ALL after blinatumomab failure is poor and treatment of these patients remains an unmet medical need. Our findings indicate that blinatumomab therapy would not exclude a significant number of patients from the potential benefit of subsequent CD19-directed therapies such as chimeric antigen receptor T-cell therapy.
- | Blincyto (blinatumomab) / Astellas, Amgen
TKI+steroid induction followed by blinatumomab + concurrent TKI consolidation. IT therapy incorporated throughout treatment. (Twitter) - Apr 28, 2019
- | Blincyto (blinatumomab) / Astellas, Amgen
Clinical, Journal: Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. (Pubmed Central) - Apr 28, 2019
Our findings indicate that blinatumomab therapy would not exclude a significant number of patients from the potential benefit of subsequent CD19-directed therapies such as chimeric antigen receptor T-cell therapy. No abstract available
- | Removab (catumaxomab) / NeoPharm, Trion, Blincyto (blinatumomab) / Astellas, Amgen
Review, Journal: Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow. (Pubmed Central) - Apr 25, 2019
Furthermore, approximately 60 bsAbs are under investigation in clinical trials. The current review aims at portraying different formats of the single-chain variable fragment (scFv)-based bsAbs and shedding light on the scFv-based bsAbs in preclinical development, different phases of clinical trials, and the market.
- | Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Review, Journal: Treatment of relapsed/refractory acute lymphoblastic leukemia. (Pubmed Central) - Apr 19, 2019
Advances in the development of novel targeted therapies have significantly improved outcomes in R/R ALL. Blinatumomab, inotuzumab ozogamicin, and chimeric antigen receptor (CAR) T-cell therapy constitute new treatment modalities that are challenging the historical regimens and paving a new path for treating patients with R/R ALL.
- | Blincyto (blinatumomab) / Astellas, Amgen
Journal: Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in MLL-rearranged infant ALL. (Pubmed Central) - Apr 19, 2019
Blinatumomab, inotuzumab ozogamicin, and chimeric antigen receptor (CAR) T-cell therapy constitute new treatment modalities that are challenging the historical regimens and paving a new path for treating patients with R/R ALL. No abstract available
- ||||| Kymriah (tisagenlecleucel-T) / Novartis
Trial completion date, Trial initiation date, Trial primary completion date: OBERON: Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 18, 2019
P3, N=220, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
No abstract available Trial completion date: Feb 2023 --> Nov 2023 | Initiation date: Mar 2019 --> Oct 2019 | Trial primary completion date: Feb 2023 --> Nov 2023
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date, Combination therapy: Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 16, 2019
P1, N=20, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Trial completion date: Feb 2023 --> Nov 2023 | Initiation date: Mar 2019 --> Oct 2019 | Trial primary completion date: Feb 2023 --> Nov 2023 Trial completion date: Nov 2019 --> May 2020 | Trial primary completion date: Nov 2018 --> May 2020
- | Blincyto (blinatumomab) / Astellas, Amgen
New P3 trial, Combination therapy: AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 16, 2019
P3, N=6720, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | Blincyto (blinatumomab) / Astellas, Amgen
Clinical, PK/PD data, Journal: Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients With Non-Hodgkin Lymphoma. (Pubmed Central) - Apr 12, 2019
Transient cytokine elevation increased with dose; it was less pronounced at low starting dose. Tumor response was a function of exposure, suggesting utility for the PK/PD relationship in dose selection for future studies, including NHL and other malignant settings.
- | Blincyto (blinatumomab) / Astellas, Amgen
Journal, Adverse events: Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. (Pubmed Central) - Apr 9, 2019
P3
These data further support the role of blinatumomab as an efficacious and well-tolerated treatment option for patients with r/r Ph ALL. This trial was registered at www.clinicaltrials.gov as #NCT02013167.
- | Blincyto (blinatumomab) / Astellas, Amgen, Keytruda (pembrolizumab) / Merck (MSD)
Trial initiation date, Combination therapy, PD(L)-1 Biomarker: Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 3, 2019
P1/2, N=36, Not yet recruiting, Sponsor: City of Hope Medical Center
This trial was registered at www.clinicaltrials.gov as #NCT02013167. Initiation date: Dec 2018 --> Apr 2019
- |||| Blincyto (blinatumomab) / Astellas, Amgen
FDA event: Blinatumomab - First approved CD3 biospecifc in US. FDA approvals #AACR19 (Twitter) - Mar 30, 2019
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: EWALL-BOLD: Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab (clinicaltrials.gov) - Mar 29, 2019
P2, N=50, Recruiting, Sponsor: Goethe University
Initiation date: Dec 2018 --> Apr 2019 Not yet recruiting --> Recruiting
- || Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 27, 2019
P1b/2, N=66, Active, not recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2019 --> Feb 2019
- ||| Blincyto (blinatumomab) / Astellas, Amgen
Trial completion, Minimal residual disease: Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Feb 26, 2019
P2, N=116, Completed, Sponsor: Amgen Research (Munich) GmbH
Trial primary completion date: Jul 2019 --> Feb 2019 Active, not recruiting --> Completed
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Blincyto (blinatumomab) / Astellas, Amgen
New P2 trial: HAP2HCT: TCR??-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies (clinicaltrials.gov) - Feb 21, 2019
P2, N=140, Recruiting, Sponsor: St. Jude Children's Research Hospital
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date: Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Feb 20, 2019
P1, N=15, Recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Trial completion date: Sep 2021 --> Dec 2022 | Trial primary completion date: Jan 2019 --> Dec 2019
- || Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date, Minimal residual disease: Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT) (clinicaltrials.gov) - Feb 18, 2019
P2, N=90, Recruiting, Sponsor: Amgen
Trial completion date: Sep 2021 --> Dec 2022 | Trial primary completion date: Jan 2019 --> Dec 2019 Trial completion date: May 2021 --> Dec 2025 | Trial primary completion date: Sep 2020 --> Mar 2025
- || Blincyto (blinatumomab) / Astellas, Amgen, blinatumomab subcutaneous / Amgen
Enrollment change: A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 15, 2019
P1b, N=54, Recruiting, Sponsor: Amgen
Trial completion date: May 2021 --> Dec 2025 | Trial primary completion date: Sep 2020 --> Mar 2025 N=33 --> 54
- |||| Kymriah (tisagenlecleucel-T) / Novartis
Trial primary completion date: OBERON: Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 5, 2019
P3, N=220, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
N=33 --> 54 Trial primary completion date: Feb 2021 --> Feb 2023
- | Blincyto (blinatumomab) / Astellas, Amgen, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
New P1 trial: BET2017: Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jan 29, 2019
P1, N=13, Recruiting, Sponsor: A.O. Ospedale Papa Giovanni XXIII
- | Blincyto (blinatumomab) / Astellas, Amgen
Journal: A novel drug interaction between busulfan and blinatumomab. (Pubmed Central) - Jan 17, 2019
This represents a unique pharmacologic consideration in hematopoietic stem cell transplantation which would impact several drugs that undergo CYP3A4 metabolism, including calcineurin inhibitors, cyclophosphamide, sirolimus, and triazole antifungals. Additionally, this mechanism of CYP3A4 suppression may be relevant in treatments and disease states where cytokine levels are elevated such as haploidentical stem cell transplantation, graft-versus-host disease, and use of chimeric antigen receptor T-cell therapy.
- | Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Enrollment open: A041703: Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 16, 2019
P2, N=64, Recruiting, Sponsor: National Cancer Institute (NCI)
Additionally, this mechanism of CYP3A4 suppression may be relevant in treatments and disease states where cytokine levels are elevated such as haploidentical stem cell transplantation, graft-versus-host disease, and use of chimeric antigen receptor T-cell therapy. Not yet recruiting --> Recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment change, Trial withdrawal, Combination therapy, PD(L)-1 Biomarker: Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 15, 2019
P1/2, N=0, Withdrawn, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting N=35 --> 0 | Not yet recruiting --> Withdrawn
- | Blincyto (blinatumomab) / Astellas, Amgen, Actemra IV (tocilizumab) / Roche, JW Pharma, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Review, Journal: No free rides: management of toxicities of novel immunotherapies in ALL, including financial. (Pubmed Central) - Jan 11, 2019
Blinatumomab, a monoclonal antibody targeting CD19, is associated with cytokine release syndrome (CRS) and neurotoxicity, both of which require prompt recognition and management primarily with corticosteroids...Tocilizumab, an interleukin-6 receptor blocker, is used to treat severe CRS from CAR-T, whereas corticosteroids remain the mainstay for neurotoxicity management. Although effective, these drugs carry a high price tag, and we review the available data on cost-effectiveness of these agents, keeping in mind that median follow-up on most of these studies is limited and that long-term data on durability of response remain to be seen.
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Blincyto (blinatumomab) / Astellas, Amgen
Enrollment change, Trial completion date, Trial primary completion date: Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Na (clinicaltrials.gov) - Jan 8, 2019
P2, N=52, Recruiting, Sponsor: St. Jude Children's Research Hospital
Although effective, these drugs carry a high price tag, and we review the available data on cost-effectiveness of these agents, keeping in mind that median follow-up on most of these studies is limited and that long-term data on durability of response remain to be seen. N=18 --> 52 | Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2019 --> Jun 2020
- | Blincyto (blinatumomab) / Astellas, Amgen, blinatumomab subcutaneous / Amgen
Trial completion date, Trial primary completion date: A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 7, 2019
P1b, N=33, Recruiting, Sponsor: Amgen
N=18 --> 52 | Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2019 --> Jun 2020 Trial completion date: May 2020 --> May 2021 | Trial primary completion date: May 2020 --> May 2021
- | Blincyto (blinatumomab) / Astellas, Amgen
Clinical, Journal: Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia. (Pubmed Central) - Jan 5, 2019
Leukemia accepted article preview online, 09 October 2017. doi:10.1038/leu.2017.306.
- | Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Clinical, Review, Journal: Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia. (Pubmed Central) - Dec 22, 2018
Novel antibody constructs such as inotuzumab ozogamicin and blinatumomab as well as potent later-generation tyrosine kinase inhibitors such as ponatinib hold significant promise in the management of ALL in the older adult. Innovative combination strategies may further improve the outcomes of these patients.
- |||| Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date: Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL (clinicaltrials.gov) - Dec 19, 2018
P2/3, N=332, Recruiting, Sponsor: Amgen
Innovative combination strategies may further improve the outcomes of these patients. Trial completion date: Aug 2021 --> Nov 2021 | Trial primary completion date: May 2021 --> Sep 2021
- || Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date, Combination therapy: HARBOUR: Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Dec 14, 2018
P1b, N=86, Recruiting, Sponsor: Amgen
Trial completion date: Aug 2021 --> Nov 2021 | Trial primary completion date: May 2021 --> Sep 2021 Trial primary completion date: Jul 2020 --> Dec 2020
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 13, 2018
P3, N=598, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2020 --> Dec 2020 Trial primary completion date: Mar 2022 --> Oct 2022
- ||| Blincyto (blinatumomab) / Astellas, Amgen
Enrollment closed, Enrollment change: Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 12, 2018
P1b/2, N=66, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Mar 2022 --> Oct 2022 Recruiting --> Active, not recruiting | N=122 --> 66